Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Peer Review reports

Original Submission
24 Dec 2013	Submitted	Original manuscript
4 Feb 2014	Reviewed	Reviewer Report - Wataru Ichikawa
17 Feb 2014	Reviewed	Reviewer Report - Sook-Ryun Park
24 Feb 2014	Author responded	Author comments - John Souglakos
Resubmission - Version 2
24 Feb 2014	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
6 Mar 2014	Reviewed	Reviewer Report - Wataru Ichikawa
19 Mar 2014	Reviewed	Reviewer Report - Sook-Ryun Park
1 Apr 2014	Author responded	Author comments - John Souglakos
Resubmission - Version 4
1 Apr 2014	Submitted	Manuscript version 4
9 Apr 2014	Author responded	Author comments - John Souglakos
Resubmission - Version 5
9 Apr 2014	Submitted	Manuscript version 5
Publishing
16 Apr 2014	Editorially accepted
22 Apr 2014	Article published	10.1186/1471-2407-14-277

Back to article page